The Evolution of the Treatment Landscape for Follicular Lymphoma

Investigators can restart the phase 3 ALLELE trial assessing tabelecleucel for patients with EBV-related posttransplant lymphoproliferative disease.

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

Results from the phase 3 HD21 trial showed that brentuximab vedotin plus chemotherapy was superior to alternative treatments in Hodgkin lymphoma.

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Diagnostic developments using aberrances in biomarker testing may help enhance survival in patients with rare lymphoma subtypes.

At the indication of the FDA and EMA, the phase 3 FLASH2 trial will further evaluate synthetic hypericin in early-stage cutaneous T-cell lymphoma.